Singapore – BluMaiden Biosciences Pte Ltd, a Singapore headquartered early-stage AI-powered biotechnology platform company, is pleased to announce a significant collaboration with A*STAR's Singapore Institute for Clinical Sciences (SICS).
This collaboration marks a pivotal milestone in the Growing Up in Singapore Towards healthy Outcomes (GUSTO) cohort study. The joint effort aims to delve into the crucial area of the microbiome's impact on the bone and metabolic health of Asian women. Asian women face unique challenges concerning bone health and chronic noncommunicable diseases, which can significantly impact their overall well-being. By conducting an in-depth examination of gut microbiome composition and functionality within the prospective cohort of Asian women of reproductive age, this study strives to unravel potential correlations and shed light on the underlying mechanisms.
BluMaiden Biosciences will leverage their state-of-the-art proprietary microbiome analytics platforms to conduct extensive research on samples obtained from the study. The collaboration unites the exceptional scientific expertise of BluMaiden Biosciences and SICS, as both teams work diligently to advance scientific knowledge and discovery by unravelling complex relationships between the gut microbiome and women’s bone and metabolic health.
"We extend our heartfelt congratulations to SICS, as well as the entire BluMaiden Biosciences team on this joint endeavour," said Dr Damien Keogh, Director and CEO at BluMaiden Biosciences. "Through this collaboration, we aim to achieve ground-breaking insights into the role of the microbiome in bone health and metabolism among Asian women. Our joint efforts have the potential to drive transformative scientific advancements that will positively impact the lives of millions."
BluMaiden Biosciences and SICS are committed to fostering collaborations that bridge the gap between cutting-edge research and practical applications, ultimately benefiting individuals and societies. This partnership signifies a shared vision to address unmet medical needs and unlock a deeper understanding of the human microbiome's impact on health.
About BluMaiden Biosciences
BluMaiden Biosciences is a biotechnology company that focuses on identifying small molecule candidate therapeutics generated by the human microbiome, with the aim of targeting various diseases. Their AI-powered platform technology accesses the depths of this unique chemical space. BluMaiden is dedicated to improving patient outcomes through advanced data analysis. The company has successfully applied this powerful technology to offer clinical trial analysis as a service for the Biotech and Pharma industry. With a sustainable business model and the support of a distinguished panel of global investors and scientific advisors, BluMaiden is actively building an enduring competitive advantage. For additional information, please visit: blumaiden.com and LinkedIn.